Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Shares

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. NYSE: MRK. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.

Merck & Co., Inc. Stock Performance

MRK stock traded down $1.77 during midday trading on Friday, hitting $75.88. The company's stock had a trading volume of 15,605,903 shares, compared to its average volume of 12,148,170. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock has a market cap of $190.54 billion, a price-to-earnings ratio of 11.27, a PEG ratio of 0.77 and a beta of 0.43. Merck & Co., Inc. has a 1 year low of $75.83 and a 1 year high of $134.63. The stock's 50-day moving average price is $85.60 and its 200 day moving average price is $93.52.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $2.07 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its board has authorized a stock repurchase program on Tuesday, January 28th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its shares are undervalued.

Analysts Set New Price Targets

MRK has been the topic of several recent analyst reports. TD Cowen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and dropped their price objective for the company from $121.00 to $100.00 in a research report on Monday, February 10th. Citigroup cut their target price on Merck & Co., Inc. from $125.00 to $115.00 and set a "buy" rating on the stock in a research note on Wednesday, February 5th. BMO Capital Markets lowered their price target on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research report on Wednesday, February 5th. Bank of America decreased their price objective on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research note on Wednesday, February 5th. Finally, StockNews.com lowered shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 25th. Twelve investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $111.13.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the transaction, the senior vice president now owns 7,778 shares in the company, valued at $643,707.28. This represents a 35.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company's stock.

Institutional Trading of Merck & Co., Inc.

Several hedge funds have recently modified their holdings of MRK. CGN Advisors LLC raised its holdings in Merck & Co., Inc. by 0.4% during the 4th quarter. CGN Advisors LLC now owns 26,969 shares of the company's stock worth $2,683,000 after buying an additional 102 shares during the period. Cypress Wealth Services LLC raised its position in Merck & Co., Inc. by 3.1% during the fourth quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company's stock worth $362,000 after acquiring an additional 111 shares in the last quarter. TI Trust Inc. lifted its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. TI Trust Inc. now owns 19,834 shares of the company's stock valued at $1,973,000 after purchasing an additional 111 shares during the last quarter. Hengehold Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. Hengehold Capital Management LLC now owns 39,989 shares of the company's stock worth $3,978,000 after acquiring an additional 112 shares during the period. Finally, Peterson Wealth Services lifted its stake in shares of Merck & Co., Inc. by 0.5% during the 4th quarter. Peterson Wealth Services now owns 21,479 shares of the company's stock worth $2,137,000 after buying an additional 113 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.